To date, studies have focused on the role of ZEB1 in mediating EMT in both prostate cancer progression (Drake et al., 2009) and docetaxel resistance (Marín‐Aguilera et al., 2014), with little known about the role of ZEB2. Here, ZEB2 is linked to prostate carcinoma.